The Impact of Modifying Sunitinib Treatment Scheduling on Renal Cancer Tumor Biology and Resistance
With sunitinib treatment of metastatic renal cell carcinoma, most patients end up developing resistance over time. Recent clinical trials have shown that individualizing treatment protocols could delay resistance and result in better outcomes. We developed an in vivo xenograft tumor model and compar...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-01-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/11/2/369 |
| _version_ | 1797493064771567616 |
|---|---|
| author | Harrison Sicheng Lin Qiang Ding Zsuzsanna Lichner Sung Sun Kim Rola Saleeb Mina Farag Ashley Di Meo Pamela Plant Mirit Kaldas Georg Arnold Bjarnason George Makram Yousef |
| author_facet | Harrison Sicheng Lin Qiang Ding Zsuzsanna Lichner Sung Sun Kim Rola Saleeb Mina Farag Ashley Di Meo Pamela Plant Mirit Kaldas Georg Arnold Bjarnason George Makram Yousef |
| author_sort | Harrison Sicheng Lin |
| collection | DOAJ |
| description | With sunitinib treatment of metastatic renal cell carcinoma, most patients end up developing resistance over time. Recent clinical trials have shown that individualizing treatment protocols could delay resistance and result in better outcomes. We developed an in vivo xenograft tumor model and compared tumor growth rate, morphological, and transcriptomic differences between alternative and traditional treatment schedules. Our results show that the alternative treatment regime could delay/postpone cancer progression. Additionally, we identified distinct morphological changes in the tumor with alternative and traditional treatments, likely due to the significantly dysregulated signaling pathways between the protocols. Further investigation of the signaling pathways underlying these morphological changes may lead potential therapeutic targets to be used in a combined treatment with sunitinib, which offers promise in postponing/reversing the resistance of sunitinib. |
| first_indexed | 2024-03-10T01:14:38Z |
| format | Article |
| id | doaj.art-e1919bf398534ca48c8ab160ec77dde7 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-10T01:14:38Z |
| publishDate | 2022-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-e1919bf398534ca48c8ab160ec77dde72023-11-23T14:12:51ZengMDPI AGJournal of Clinical Medicine2077-03832022-01-0111236910.3390/jcm11020369The Impact of Modifying Sunitinib Treatment Scheduling on Renal Cancer Tumor Biology and ResistanceHarrison Sicheng Lin0Qiang Ding1Zsuzsanna Lichner2Sung Sun Kim3Rola Saleeb4Mina Farag5Ashley Di Meo6Pamela Plant7Mirit Kaldas8Georg Arnold Bjarnason9George Makram Yousef10The Keenan Research Centre for Biomedical Science, St. Michael’s Hospital, Toronto, ON M5B 1W8, CanadaThe Keenan Research Centre for Biomedical Science, St. Michael’s Hospital, Toronto, ON M5B 1W8, CanadaThe Keenan Research Centre for Biomedical Science, St. Michael’s Hospital, Toronto, ON M5B 1W8, CanadaThe Keenan Research Centre for Biomedical Science, St. Michael’s Hospital, Toronto, ON M5B 1W8, CanadaThe Keenan Research Centre for Biomedical Science, St. Michael’s Hospital, Toronto, ON M5B 1W8, CanadaThe Keenan Research Centre for Biomedical Science, St. Michael’s Hospital, Toronto, ON M5B 1W8, CanadaThe Keenan Research Centre for Biomedical Science, St. Michael’s Hospital, Toronto, ON M5B 1W8, CanadaThe Keenan Research Centre for Biomedical Science, St. Michael’s Hospital, Toronto, ON M5B 1W8, CanadaThe Keenan Research Centre for Biomedical Science, St. Michael’s Hospital, Toronto, ON M5B 1W8, CanadaSunnybrook Odette Cancer Centre, Toronto, ON M4N 3M5, CanadaThe Keenan Research Centre for Biomedical Science, St. Michael’s Hospital, Toronto, ON M5B 1W8, CanadaWith sunitinib treatment of metastatic renal cell carcinoma, most patients end up developing resistance over time. Recent clinical trials have shown that individualizing treatment protocols could delay resistance and result in better outcomes. We developed an in vivo xenograft tumor model and compared tumor growth rate, morphological, and transcriptomic differences between alternative and traditional treatment schedules. Our results show that the alternative treatment regime could delay/postpone cancer progression. Additionally, we identified distinct morphological changes in the tumor with alternative and traditional treatments, likely due to the significantly dysregulated signaling pathways between the protocols. Further investigation of the signaling pathways underlying these morphological changes may lead potential therapeutic targets to be used in a combined treatment with sunitinib, which offers promise in postponing/reversing the resistance of sunitinib.https://www.mdpi.com/2077-0383/11/2/369renal cell carcinomasunitinibresistancetreatment scheduling |
| spellingShingle | Harrison Sicheng Lin Qiang Ding Zsuzsanna Lichner Sung Sun Kim Rola Saleeb Mina Farag Ashley Di Meo Pamela Plant Mirit Kaldas Georg Arnold Bjarnason George Makram Yousef The Impact of Modifying Sunitinib Treatment Scheduling on Renal Cancer Tumor Biology and Resistance Journal of Clinical Medicine renal cell carcinoma sunitinib resistance treatment scheduling |
| title | The Impact of Modifying Sunitinib Treatment Scheduling on Renal Cancer Tumor Biology and Resistance |
| title_full | The Impact of Modifying Sunitinib Treatment Scheduling on Renal Cancer Tumor Biology and Resistance |
| title_fullStr | The Impact of Modifying Sunitinib Treatment Scheduling on Renal Cancer Tumor Biology and Resistance |
| title_full_unstemmed | The Impact of Modifying Sunitinib Treatment Scheduling on Renal Cancer Tumor Biology and Resistance |
| title_short | The Impact of Modifying Sunitinib Treatment Scheduling on Renal Cancer Tumor Biology and Resistance |
| title_sort | impact of modifying sunitinib treatment scheduling on renal cancer tumor biology and resistance |
| topic | renal cell carcinoma sunitinib resistance treatment scheduling |
| url | https://www.mdpi.com/2077-0383/11/2/369 |
| work_keys_str_mv | AT harrisonsichenglin theimpactofmodifyingsunitinibtreatmentschedulingonrenalcancertumorbiologyandresistance AT qiangding theimpactofmodifyingsunitinibtreatmentschedulingonrenalcancertumorbiologyandresistance AT zsuzsannalichner theimpactofmodifyingsunitinibtreatmentschedulingonrenalcancertumorbiologyandresistance AT sungsunkim theimpactofmodifyingsunitinibtreatmentschedulingonrenalcancertumorbiologyandresistance AT rolasaleeb theimpactofmodifyingsunitinibtreatmentschedulingonrenalcancertumorbiologyandresistance AT minafarag theimpactofmodifyingsunitinibtreatmentschedulingonrenalcancertumorbiologyandresistance AT ashleydimeo theimpactofmodifyingsunitinibtreatmentschedulingonrenalcancertumorbiologyandresistance AT pamelaplant theimpactofmodifyingsunitinibtreatmentschedulingonrenalcancertumorbiologyandresistance AT miritkaldas theimpactofmodifyingsunitinibtreatmentschedulingonrenalcancertumorbiologyandresistance AT georgarnoldbjarnason theimpactofmodifyingsunitinibtreatmentschedulingonrenalcancertumorbiologyandresistance AT georgemakramyousef theimpactofmodifyingsunitinibtreatmentschedulingonrenalcancertumorbiologyandresistance AT harrisonsichenglin impactofmodifyingsunitinibtreatmentschedulingonrenalcancertumorbiologyandresistance AT qiangding impactofmodifyingsunitinibtreatmentschedulingonrenalcancertumorbiologyandresistance AT zsuzsannalichner impactofmodifyingsunitinibtreatmentschedulingonrenalcancertumorbiologyandresistance AT sungsunkim impactofmodifyingsunitinibtreatmentschedulingonrenalcancertumorbiologyandresistance AT rolasaleeb impactofmodifyingsunitinibtreatmentschedulingonrenalcancertumorbiologyandresistance AT minafarag impactofmodifyingsunitinibtreatmentschedulingonrenalcancertumorbiologyandresistance AT ashleydimeo impactofmodifyingsunitinibtreatmentschedulingonrenalcancertumorbiologyandresistance AT pamelaplant impactofmodifyingsunitinibtreatmentschedulingonrenalcancertumorbiologyandresistance AT miritkaldas impactofmodifyingsunitinibtreatmentschedulingonrenalcancertumorbiologyandresistance AT georgarnoldbjarnason impactofmodifyingsunitinibtreatmentschedulingonrenalcancertumorbiologyandresistance AT georgemakramyousef impactofmodifyingsunitinibtreatmentschedulingonrenalcancertumorbiologyandresistance |